Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-04-01

Clinical Trial Update: Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression [Phase 3]

View source ↗

Summary

A 24-week extension study of lurasidone in adults with Bipolar I Depression reports long-term safety and efficacy data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Latuda (lurasidone)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Bipolar Depression | Phase 3 | Status: COMPLETED | Results posted: 2014-04-01